NasdaqCM:OCGNBiotechs
Assessing Ocugen (OCGN) Valuation After Positive OCU410 Gene Therapy Data And Equity Raise
Ocugen (OCGN) is back on the radar after reporting preliminary 12 month data for its OCU410 gene therapy in geographic atrophy, alongside a recent US$22.5 million follow on equity offering at US$1.50 per share.
See our latest analysis for Ocugen.
Ocugen’s latest OCU410 trial update and the US$22.5 million equity raise come after a period where the stock has seen a 20.29% year to date share price return and a very large 112.82% one year total shareholder return. This suggests recent news is...